The report below gives a good overview of the Winter 2023 M&A activity in the Healthcare & Life Sciences Industry Sector. The global healthcare and life sciences sector is impacted by rising energy prices, and inflation. However, the sector has historically outperformed compared to other sectors during economic downturns by increased investments in innovation, growth, and improved products to meet patient needs. Recent COVID-19 cases surge in China has led authorities in the country to add hospital beds, build fever clinics, and set up more intensive care facilities which is expected to bolster the demand in the healthcare and life sciences sector. Currently, businesses are expected to spend more on digital technologies, attempt to improve supply chain resilience and recruit individuals with digital technology knowledge. Wearables, digital assistants, and smart gadgets are being used more often than ever to evaluate fitness and health improvement. Additionally, the global healthcare and life sciences sector is moving towards decarbonization strategies by transitioning from fossil fuels and disposables to sustainable renewable alternatives and reusable instruments respectively. In 2023, it is expected that new regulations will impact business operations in the industry. For instance, the new transparency regulations adopted in the US will enable increased data exchange globally. Additionally, the Inflation Reduction Act of 2022 includes several provisions aimed at lowering the price of prescription drugs for Medicare beneficiaries and the federal government. Furthermore, rapid advances in technology and artificial intelligence across organizations in the healthcare sector is expected to fuel industry growth by leveraging online and remote patient evaluation, diagnosis, and treatment.
Posted by Daniel Sirvent.